Myeloma Center

You are here

News

Multi-Color Capsule
Despite advancements in myeloma treatment, patients often experience disease recurrence and progression that necessitates successive therapeutic intervention. With exposure to each additional therapy, patients may be subject to additional side effects and comorbidities, potentially leading to frailty that can limit further treatment options. Thus, a pressing challenge in the relapsed/refractory myeloma setting is to find effective treatment regimens with a manageable toxicity profile.To address...
Walking
Physical activity offers a host of bodily benefits, including but not limited to increased strength and ease of movement, and improved efficiency of the heart and lungs. It can also reduce stress and boost energy and confidence.Exercise is an essential component of any healthy lifestyle – but a lack of exercise can lead to loss of strength and mobility, and a lack of effective oxygen utilization. For people with cancer, inactivity and deconditioning can hinder your overall performance status,...
Amyloidosis is a rare disease characterized by a buildup of abnormal proteins called amyloids within organs like the heart, kidneys and liver. The Myeloma Center’s Dr. Cara Rosenbaum specializes in the care and treatment of people with amyloidosis and is a long-time partner of the nationwide patient support and advocacy organization, Amyloidosis Support Groups, facilitiated by Muriel Finkel. The amyloidosis support group meeting took place on the Weill Cornell Medicine/NewYork-Presbyterian...
Cells
Three-drug combinations have demonstrated benefit both for newly diagnosed myeloma patients who go on to undergo autologous stem cell transplantation, as well as for those who are transplant-ineligible. Often included in these triplet combinations is a proteasome inhibitor. Proteasome is the protein complex responsible for maintaining cell homeostasis by disposing of proteins not useful to the body. Proteasome inhibitors -- which have become a staple of myeloma treatment -- work by impeding...
Renal impairment, a common comorbidity of multiple myeloma, occurs when the body’s kidneys cannot efficiently filter waste products from the blood. Associated with poor survival outcomes, renal impairment can limit treatment options, as well as complicate dosing for people with myeloma.In search of more effective and well-tolerated therapies for myeloma patients with renal impairment, Dr. Ruben Niesvizky and colleagues analyzed the results of the phase III ENDEAVOR study – a comparison of...
Each year, the American Society of Hematology (ASH) Annual Meeting and Exposition convenes over 25,000 clinicians and scientists from around the world to discuss the latest research into the treatment of blood diseases. This year’s 60th Annual ASH Meeting brought exciting advancements with potential to improve care for people with myeloma, amyloidosis and other plasma cell disorders. Here are some research highlights from the meeting.Emerging Treatment Technology: BiTEsAlmost all myeloma cells...
Tour Our New Home
The Weill Cornell Medicine Myeloma Center's new home on 425 E 61st Street features semi-private infusion spaces, a dedicated social worker, and more! Join the Center's Director, Dr. Ruben Niesvizky, and Associate Director, Dr. Adriana Rossi, for a virtual tour. Video of Weill Cornell Medicine Myeloma Center Tour
Drs. Rossi and Monge standing at a podium.
The national Multiple Myeloma Rounds Program was established in 2016 to provide a forum for local healthcare professionals to address specific issues related to the diagnosis and treatment of multiple myeloma patients. At the recent CME-accredited Multiple Myeloma Rounds Program in New York City, several key opinion leaders and subject matter experts were invited to speak about topics related to myeloma patient care and treatment.
Tubes in a bundle.
Dr. Ruben Niesvizky, Weill Cornell Medicine Myeloma Center Director, and Dr. Kenar Jhaveri, nephrologist and Professor of Medicine in the Division of Kidney Diseases and Hypertension at Hofstra and Northwell Health, published an editorial in the Journal of the American Medical Association (JAMA) addressing the role of using a special form of hemodialysis in myeloma patients with kidney damage.
Myeloma Research Updates at the 2017 American Society of Hematology Annual Meeting
Researchers and physicians at the Weill Cornell Medicine and NewYork-Presbyterian Multiple Myeloma Center presented cutting-edge research at this year’s American Society of Hematology (ASH) Annual Meeting and Exposition, an educational gathering of over 25,000 clinicians and scientists from around the world who are working to conquer blood disease.

Weill Cornell Medicine Myeloma Center 425 East 61st St
8th Floor
New York, NY 10065 Phone: (646) 962-6500 Fax: (212) 746-8961